8-K: Immunome Announces Public Offering and Provides Pipeline Update

Immunome, Inc. announces an underwritten public offering of its common stock and provides an update on its clinical and preclinical oncology pipeline.

Summary

• Immunome, Inc. announced the commencement of an underwritten public offering of its common stock.
• The company expects to report approximately $217.3 million in cash, cash equivalents, and marketable securities as of December 31, 2024, based on preliminary estimates.
• Immunome is focused on developing targeted oncology therapies and is advancing a pipeline of clinical and preclinical assets.
• The company's lead clinical asset, varegacestat, is currently under evaluation in a Phase 3 trial for the treatment of desmoid tumors, with topline data expected in the second half of 2025.
• An IND for IM-1021, a ROR1 antibody-drug conjugate (ADC), received clearance in December 2024, and a Phase 1 trial is expected to begin in the first quarter of 2025.
• Immunome anticipates submitting an IND for IM-3050, a FAP-targeted radioligand therapy (RLT), in the first quarter of 2025.
• The company also has three solid tumor ADC potential drug candidates: IM-1617, IM-1340, and IM-1335, all of which are in IND-enabling manufacturing.
• Six additional ADCs are currently undergoing lead optimization with development decisions expected later this year and into 2026.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting pipeline progress and a strong cash position, but tempered by the need for a public offering and the inherent risks of drug development.

Positives

• Immunome has a strong cash position, with an estimated $217.3 million in cash, cash equivalents, and marketable securities.
• The company has a diverse pipeline of clinical and preclinical assets targeting various cancers.
• The Phase 3 trial for varegacestat is fully enrolled, indicating progress in its clinical development.
• The IND clearance for IM-1021 allows the company to initiate a Phase 1 trial in the near term.
• Preclinical data for IM-1617 and IM-1340 show promising efficacy and tolerability.

Negatives

• The financial statements for the quarter and year ended December 31, 2024, will not be available prior to investing in the common stock offering.
• The estimated cash balance is preliminary and subject to final adjustments.
• The company is reliant on the success of its pipeline assets, which are subject to clinical and regulatory risks.

Risks

• The company's preliminary financial results are subject to change and may not be indicative of future performance.
• Regulatory approvals for the company's programs and product candidates may be delayed or not obtained.
• Pre-clinical data may not be predictive of clinical data.
• The company's product candidates and development candidates may fail to achieve their intended endpoints.
• The company's capital requirements and expected cash runway are subject to uncertainties.

Future Outlook

Immunome plans to continue advancing its pipeline of oncology therapies, including initiating clinical trials for IM-1021 and submitting an IND for IM-3050 in the first quarter of 2025, and reporting topline data from the Phase 3 trial of varegacestat in the second half of 2025.

Industry Context

Immunome is operating in the competitive biotechnology industry, focusing on developing targeted oncology therapies, including ADCs and RLTs, which are areas of significant interest and investment in the pharmaceutical sector.

Comparison to Industry Standards

• Immunome's approach of developing ADCs with novel targets and payloads like HC74 is in line with industry trends.
• HC74 is being compared to DXd, the TOP1 inhibitor incorporated into Enhertu, a successful ADC developed by Daiichi Sankyo and AstraZeneca.
• The company's focus on FAP-targeted RLTs is similar to efforts by other companies in the radiopharmaceutical space, such as Novartis with its Pluvicto product.

Stakeholder Impact

• Shareholders will be impacted by the public offering and the company's progress in developing its pipeline.
• Employees will be impacted by the company's growth and development activities.
• Patients may benefit from the development of new cancer therapies.

Next Steps

• File a preliminary prospectus supplement with the SEC.
• Initiate a Phase 1 clinical trial for IM-1021 in the first quarter of 2025.
• Submit an IND for IM-3050 in the first quarter of 2025.
• Report topline data from the Phase 3 RINGSIDE Part B trial for varegacestat in the second half of 2025.
• Continue IND-enabling work for IM-1617 and IM-1340.
• Make development decisions on six additional ADCs currently undergoing lead optimization.

Key Dates